Centessa doses first subject in registrational PRESent-2 study for SerpinPC in hemophilia B

Centessa Pharmaceuticals plc

Dosed first patient in PRESent-2, a Phase 2b registrational study of SerpinPC for hemophilia B without inhibitors.
Interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of the adaptive design.
SerpinPC is a subcutaneously administered APC inhibitor; potential first-in-class therapy for hemophilia B.
Company expects to start registrational PRESent-3 study for hemophilia B with inhibitors later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.